Literature DB >> 28003113

Lymphoma in Taiwan: Review of 1347 neoplasms from a single institution according to the 2016 Revision of the World Health Organization Classification.

Shih-Sung Chuang1, Shang-Wen Chen2, Sheng-Tsung Chang3, Yu-Ting Kuo4.   

Abstract

BACKGROUND/
PURPOSE: Lymphoid neoplasms are heterogeneous and types of lymphoma vary in different geographic regions. In this study, we aimed at classifying the lymphoid neoplasms at our institution in Taiwan and to compare the relative frequency of various types of lymphoma in different countries.
METHODS: We retrospectively searched the files of patients diagnosed with lymphoma at our institution from 2000 to 2015 based on the 2016 Revision of the World Health Organization classification.
RESULTS: We identified 1339 patients with lymphoid neoplasms; among them, eight had two distinct types of lymphoid neoplasms. Of the 1347 neoplasms, 6.09% were Hodgkin lymphomas (HLs) and 93.31%, non-HL (NHLs). Among the 1257 NHLs, 82.66% were of B-cell lineage and 17.34% of T-cell lineage. The most common B-cell lymphoma types were diffuse large B-cell lymphoma, follicular lymphoma, and mucosa-associated lymphoid tissue lymphoma. Among T-cell neoplasms, 37% cases were of nodal origin and 63% cases arose in extranodal sites. The most common nodal and extranodal T-cell neoplasms were angioimmunoblastic T-cell lymphoma and extranodal natural killer/T-cell lymphoma, nasal type, respectively.
CONCLUSION: We analyzed the largest series of lymphomas to date from Taiwan and concluded that HL was rare and T-cell neoplasms comprised around 17% of all NHLs in Taiwan. The relative frequency of the major lymphoma types is similar in East Asian countries, with only a minor difference, but the overall pattern in the East is quite different from that in the West, with the latter showing a higher frequency of HL and a lower rate of T-cell neoplasms.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Hodgkin lymphoma; Taiwan; lymphoma; lymphoma frequency; non-Hodgkin lymphoma

Mesh:

Year:  2016        PMID: 28003113     DOI: 10.1016/j.jfma.2016.11.006

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  6 in total

1.  A G3BP1-Interacting lncRNA Promotes Ferroptosis and Apoptosis in Cancer via Nuclear Sequestration of p53.

Authors:  Chao Mao; Xiang Wang; Yating Liu; Min Wang; Bin Yan; Yiqun Jiang; Ying Shi; Yi Shen; Xiaoli Liu; Weiwei Lai; Rui Yang; Desheng Xiao; Yan Cheng; Shuang Liu; Hu Zhou; Ya Cao; Weishi Yu; Kathrin Muegge; Herbert Yu; Yongguang Tao
Journal:  Cancer Res       Date:  2018-03-27       Impact factor: 12.701

2.  Subtype-specific epidemiology of lymphoid malignancies in Taiwan compared to Japan and the United States, 2002-2012.

Authors:  Bor-Sheng Ko; Li-Ju Chen; Huai-Hsuan Huang; Yao-Chun Wen; Chi-Yin Liao; Ho-Min Chen; Fei-Yuan Hsiao
Journal:  Cancer Med       Date:  2018-10-09       Impact factor: 4.452

3.  Distinctive incidence patterns of follicular lymphoma in Taiwan: Implications of ethnic differences.

Authors:  Shang-Ju Wu; Yi-Chu Chen; Wei-Cheng Lo; Chun-Ju Chiang; Chien-Ting Lin; Shih-Sung Chuang; Mei-Shu Lai
Journal:  Cancer Med       Date:  2019-02-21       Impact factor: 4.452

4.  Increasing Incidence of B-Cell Non-Hodgkin Lymphoma and Occurrence of Second Primary Malignancies in South Korea: 10-Year Follow-up Using the Korean National Health Information Database.

Authors:  Jin Seok Kim; Yanfang Liu; Kyoung Hwa Ha; Hong Qiu; Lee Anne Rothwell; Hyeon Chang Kim
Journal:  Cancer Res Treat       Date:  2020-05-04       Impact factor: 4.679

5.  Hepatitis B surface antigen positivity is associated with progression of disease within 24 months in follicular lymphoma.

Authors:  Chieh-Lung Cheng; Wei-Quan Fang; Yu-Jen Lin; Chang-Tsu Yuan; Bor-Sheng Ko; Jih-Luh Tang; Hwei-Fang Tien
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-06       Impact factor: 4.322

6.  High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan.

Authors:  Cheng-Chih Tsai; Yung-Cheng Su; Oluwaseun Adebayo Bamodu; Bo-Jung Chen; Wen-Chiuan Tsai; Wei-Hong Cheng; Chii-Hong Lee; Shu-Min Hsieh; Mei-Ling Liu; Chia-Lang Fang; Huan-Tze Lin; Chi-Long Chen; Chi-Tai Yeh; Wei-Hwa Lee; Ching-Liang Ho; Shiue-Wei Lai; Huey-En Tzeng; Yao-Yu Hsieh; Chia-Lun Chang; Yu-Mei Zheng; Hui-Wen Liu; Yun Yen; Jacqueline Whang-Peng; Tsu-Yi Chao
Journal:  Cancers (Basel)       Date:  2021-03-31       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.